Study S000979

A Trial to Complare the Injection Site Pain Experience of Semaglutide 0.25 mg and Dulaglutide 0.75 mg Administered sc

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04189848
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 104
Start: 2019-12-03
Primary completion: 2020-01-29
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers; Diabetes Mellitus, Type 2; Overweight; Obesity
Interventions: DRUG:Semaglutide; DRUG:Dulaglutide
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2019-83003844-57; OTHER:U1111-1241-0348; NIH:2019

Registered primary outcomes

Intensity of Injection Site Pain [1 minute after each injection (Day 1)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017197	Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects. Snitker S, Diabetes, obesity & metabolism	2021	Randomized trial	PMID 33591618 DOI	registry reference RESULT:33591618